Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shot up 6.8% during trading on Wednesday . The stock traded as high as $1.3060 and last traded at $1.25. 120,896 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 147,315 shares. The stock had previously closed at $1.17.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tiziana Life Sciences in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Tiziana Life Sciences Stock Up 6.8%

The stock’s fifty day moving average price is $1.39 and its 200-day moving average price is $1.63.

Institutional Trading of Tiziana Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP boosted its stake in shares of Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after acquiring an additional 14,005 shares during the period. Millennium Management LLC bought a new stake in Tiziana Life Sciences in the 3rd quarter valued at $520,000. Jane Street Group LLC lifted its holdings in Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after purchasing an additional 151,858 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Tiziana Life Sciences by 413.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock valued at $164,000 after purchasing an additional 88,830 shares during the last quarter. Finally, Zhang Financial LLC boosted its position in Tiziana Life Sciences by 18.6% during the fourth quarter. Zhang Financial LLC now owns 99,900 shares of the company’s stock worth $149,000 after purchasing an additional 15,700 shares during the period.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.